Winchester J F, Ward D M, McKillop J H, Kennedy A C
Br J Clin Pharmacol. 1976 Oct;3(5):863-7. doi: 10.1111/j.1365-2125.1976.tb00639.x.
Ten patients not maximally controlled on an oxprenolo/cyclopenthiazide regimen for moderately severe hypertension were treated in a double blind crossover trial with either hydrallazine (75-150 mg/day) or phentolamine (60-120 mg/day) or placebo in addition to their other therapy. Additional phentolamine therapy did not lower blood pressure significantly when compared with placebo. Additional hydrallazine (75-150 mg/day) produced an approximate 10 mm, Hg fall in diastolic blood pressure, but no significant fall in systolic blood pressure. Pulse rates did not alter with the addition of hydrallazine or phentolamine. In patients who fail to attain optimal blood pressure response to beta-adrenoceptor blocking drugs it is suggested that the addition of hydrallazine is a useful measure.
在一项双盲交叉试验中，对10名使用氧烯洛尔/环戊噻嗪方案治疗中度严重高血压但血压未得到最大程度控制的患者，除其他治疗外，分别加用肼屈嗪（75 - 150毫克/天）、酚妥拉明（60 - 120毫克/天）或安慰剂进行治疗。与安慰剂相比，额外使用酚妥拉明治疗并未显著降低血压。额外使用肼屈嗪（75 - 150毫克/天）可使舒张压大约下降10毫米汞柱，但收缩压无显著下降。加用肼屈嗪或酚妥拉明后心率未改变。对于未能对β - 肾上腺素能受体阻断药获得最佳血压反应的患者，建议加用肼屈嗪是一种有用的措施。
